lactobacillus rhamnosus
Lacticaseibacillus rhamnosus is a bacterium that originally was considered to be a subspecies of L. casei, but genetic research found it to be a separate species in the L. casei clade, which also includes L. paracasei and L. zeae. It is a short Gram-positive homofermentative facultative anaerobic non-spore-forming rod that often appears in chains. Some strains of L. rhamnosus bacteria are being used as probiotics, and are particularly useful in treating infections of the female urogenital tract, most particularly very difficult to treat cases of bacterial vaginosis. The species Lacticaseibacillus rhamnosus and Limosilactobacillus reuteri are commonly found in the healthy female genito-urinary tract and are helpful to regain control of dysbiotic bacterial overgrowth during an active infection. L. rhamnosus sometimes is used in dairy products such as fermented milk and as non-starter-lactic acid bacterium (NSLAB) in long-ripened cheese. While frequently considered a beneficial organism, L. rhamnosus may not be as beneficial to certain subsets of the population; in rare circumstances, especially those primarily involving weakened immune system or infants, it may cause endocarditis. Despite the rare infections caused by L. rhamnosus, the species is included in the list of bacterial species with qualified presumed safety (QPS) status of the European Food Safety Agency. — Wikipedia
Clinical trial activity
215 trials · 248 clinical orgs · 0 marketing orgs
Earliest trial started Mar 1, 2001 (NCT00224432)
Timeline
Indications
Approved for
Studied for
- Abdominal Pain · Phase 4
- Aged · Phase 1
- Alcoholism · Phase 2
- Anxiety · Phase 2
- Asthma · Phase 4
- Atypical Squamous Cells of the Cervix · Phase 2
- Autism Spectrum Disorder · Phase 1/Phase 2
- Bacteriuria · Phase 1
- Bronchopulmonary Dysplasia · Phase 3
- Burns · Phase 2
- Candidiasis, Vulvovaginal · Phase 1
- Chronic Periodontitis · Phase 2
- Clostridioides difficile · Phase 4
- Clostridium Infections · Early Phase 1
- Colitis, Ulcerative · Phase 2
- Colonic Neoplasms · Phase 4
- Colonoscopy · Phase 2
- Colorectal Neoplasms · Phase 2
- Conjunctivitis, Allergic · Phase 2/Phase 3
- Cross Infection · Phase 3
- Cystic Fibrosis · Phase 3
- Death · Phase 4
- Dermatitis, Atopic · Phase 4
- Diabetes Mellitus, Type 1 · Phase 4
- Diabetes Mellitus, Type 2 · Phase 2
- Diarrhea · Phase 4
- Digestive System Neoplasms · Phase 4
- Drug Resistance, Bacterial · Phase 2
- Dyspepsia · Phase 1/Phase 2
- Enterocolitis · Phase 4
- Enterocolitis, Pseudomembranous · Phase 4
- Febrile Neutropenia · Phase 2
- Feces · Phase 4
- Gastroenteritis · Phase 3
- Gastroesophageal Reflux · Phase 4
- Gastrointestinal Diseases · Phase 1/Phase 2
- Gastrointestinal Microbiome · Phase 3
- Gastrointestinal Neoplasms · Phase 1/Phase 2
- Glucose Intolerance · Phase 3
- Healthy Volunteers · Phase 3
- Helicobacter pylori · Phase 4
- Hepatic Encephalopathy · Phase 1
- HIV · Phase 1/Phase 2
- HIV Infections · Phase 2/Phase 3
- Hospitalization · Phase 2
- Hyperbilirubinemia · Phase 2
- Infant, Low Birth Weight · Phase 2/Phase 3
- Infections · Phase 4
- Infertility, Female · Phase 4
- Inflammation · Phase 2
- Influenza, Human · Phase 4
- Intensive Care Units · Phase 2
- Intestinal Neoplasms · Phase 4
- Irritable Bowel Syndrome · Phase 3
- Leukomalacia, Periventricular · Phase 3
- Live Birth · Phase 3
- Liver Diseases · Phase 2
- Liver Diseases, Alcoholic · Phase 4
- Lower Urinary Tract Symptoms · Phase 2
- Mania · Phase 2
- Metabolic Syndrome · Phase 4
- Milk Hypersensitivity · Phase 2/Phase 3
- Neonatology · Phase 2
- Neoplasms · Phase 3
- Neutropenia · Phase 2
- Obesity · Phase 1/Phase 2
- Periodontitis · Phase 2
- Pneumonia · Phase 4
- Pneumonia, Ventilator-Associated · Phase 4
- Poliovirus Vaccine, Oral · Phase 4
- Pregnancy · Phase 3
- Premature Birth · Phase 3
- Probiotics · Phase 4
- Prostheses and Implants · Phase 4
- Respiratory Tract Infections · Phase 4
- Rhinitis, Allergic · Phase 3
- Rotavirus Infections · Phase 4
- Sepsis · Phase 3
- Signs and Symptoms, Digestive · Phase 1/Phase 2
- Sinusitis · Phase 4
- Spinal Cord Injuries · Phase 3
- Stress Disorders, Post-Traumatic · Phase 2
- Urinary Bladder, Neurogenic · Phase 3
- Urinary Tract Infections · Phase 2
- Vaginal Diseases · Phase 4
- Vaginosis, Bacterial · Phase 4
- Ventilators, Mechanical · Phase 2
Mechanism of action
- microbiotaTissue restoration
microbiota tissue restoration
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaLacticaseibacillus rhamnosus ↗
- WikipediaLactobacillus rhamnosus ↗
Also known as
- align
- ehcf
- lactobacilli gr-1
- lactobacillus casei rhamnosus
- lactobacillus gg
- lactobacillus gr-1
- lactobacillus rhamnosu
- lactobacillus rhamnosus
- lactobacillus rhamnosus clr2
- lactobacillus rhamnosus gg
- lactobacillus rhamnosus gg atcc 53103
- lactobacillus rhamnosus gr1
- lactobacillus rhamnosus gr-1
- lactobacillus rhamnosus, gr-1
- lactobacillus rhamnosus hn001
- lactobacillus rhamnosus pb01
- lactobacillus rhamnosus sp1
- lactobacillus rhamnosus strain gg
- lactobacillus rhamnosus w71
- l. rhamnosus
- l. rhamnosus fiti
- l. rhamnosus gg
- l. rhamnosus gr-1
- l.rhamnosus r0011 strain
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07165457 | N/A | Sep 4, 2025 | Clinica Universidad de Navarra |
| NCT07102836 | Phase 2 | Aug 7, 2025 | Quaid-e-Azam Medical College |
| NCT07081100 | N/A | Aug 5, 2025 | Wecare Probiotics Co., Ltd. |
| NCT06990568 | Phase 4 | Jun 1, 2025 | Ilsan Hospital |
| NCT06873438 | N/A | Mar 10, 2025 | Wecare Probiotics Co., Ltd. |
| NCT06872320 | N/A | Mar 1, 2025 | Chang Gung University |
| NCT07154992 | N/A | Dec 17, 2024 | Bioithas SL |
| NCT06268964 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2024 | Universidad de Colima |
| NCT06470906 | N/A | Aug 14, 2024 | Columbia University |
| NCT06899620 | N/A | Jul 1, 2024 | Wecare Probiotics Co., Ltd. |
| NCT06629441 | N/A | Jun 20, 2024 | Wecare Probiotics Co., Ltd. |
| NCT06607562 | N/A | Jun 3, 2024 | Wecare Probiotics Co., Ltd. |
| NCT07072871 | N/A | Apr 1, 2024 | PT Royal Medikalink Pharmalab |
| NCT06310733 | Phase 4 | Mar 21, 2024 | Prince of Songkla University |
| NCT07091955 | N/A | Oct 16, 2023 | Bioithas SL |
| NCT06429358 | N/A | Jun 23, 2023 | Frontier Medical and Dental College, Abbotabad |
| NCT07296718 | Phase 4 | May 15, 2023 | Islamia University of Bahawalpur |
| NCT05674981 | N/A | Apr 24, 2023 | Chung Shan Medical University, GenMont Biotech Incorporation |
| NCT05791604 | N/A | Apr 1, 2023 | Fudan University |
| NCT05517928 | N/A | Jan 31, 2023 | Mayo Clinic |
Organizations
Research & Development (248)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Naples Frederico II | Academic/Hospital | 10 | 10 | 3 | 2008 |
| University of Western Ontario | Academic/Hospital | 8 | 5 | 3 | 2007 |
| Harvard University | Academic/Hospital | 6 | 5 | 3 | 2009 |
| Medical University of Warsaw | Academic/Hospital | 6 | 6 | 2 | 2010 |
| Tufts University | Academic/Hospital | 6 | 5 | 3 | 2003 |
| Chr Hansen | For profit | 5 | 2 | 2 | 2007 |
| McMaster University | Academic/Hospital | 5 | 4 | 4 | 2013 |
| University of Copenhagen | Academic/Hospital | 5 | 4 | 2 | 2014 |
| Wecare Probiotics Co., Ltd. | For profit | 5 | 5 | 1 | 2024 |
| Department of Veteran Affairs | Government | 4 | 4 | 3 | 2008 |
| Georgetown University | Academic/Hospital | 4 | 4 | 2 | 2016 |
| University of Toronto | Academic/Hospital | 4 | 3 | 3 | 2005 |
| Baylor University | Academic/Hospital | 3 | 2 | 3 | 2008 |
| Canadian Institutes of Health Research (CIHR) | Academic/Hospital | 3 | 0 | 3 | 2005 |
| Emek Medical Center | Academic/Hospital | 3 | 3 | 1 | 2016 |
| Lallemand SAS | For profit | 3 | 1 | 2 | 2013 |
| Medical University of Graz | Academic/Hospital | 3 | 3 | 1 | 2012 |
| National Institute for Medical Research, Tanzania | Government | 3 | 1 | 2 | 2007 |
| Shriners Hospitals for Children | Academic/Hospital | 3 | 2 | 2 | 2004 |
| University of Antwerp | Academic/Hospital | 3 | 3 | 1 | 2016 |